SAKK 36/13–IBRUTINIB AND BORTEZOMIB FOLLOWED BY IBRUTINIB MAINTENANCE IN PATIENTS WITH RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: PHASE I REPORT OF A PHASE I/II TRIAL. (June 2017) - Novak, U.; Fehr, M.; Zander, T.; Winterhalder, R.; Amram, M.; Stathis, A.; Rondeau, S.; Berardi, S.; Eckhardt, K.; Driessen, C.; Renner, C.